Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Interim Dividend Timetable

26th May 2021 14:44

RNS Number : 9286Z
Vectura Group plc
26 May 2021
 

 

Vectura Group plc

Interim Dividend Timetable

Chippenham, UK - 26 May 2021: Vectura Group plc (LSE: VEC) ("Vectura "), announced earlier this morning a recommended cash acquisition by Murano Bidco Limited, and in connection therewith, announced the withdrawal of the special dividend of 19 pence per Vectura ordinary share (the "Special Dividend"), the share consolidation and the dividend reinvestment plan previously announced on 21 April 2021, and the declaration of an interim cash dividend of 19 pence per Vectura ordinary share (the "Interim Dividend") in replacement of the previous Special Dividend. The schedule below sets out the key dates in respect of the Interim Dividend.

Expected Timetable of Principal Events

 

Record Date for the Interim Dividend

6.00 p.m. on Friday, 28 May

Ordinary Shares marked ex-Interim Dividend

Tuesday, 1 June

Interim Dividend becomes payable to Shareholders

Friday, 11 June

 

- Ends -

 

For more information, please contact:

Vectura Group plc

John Murphy - Company Secretary +44 (0)207 881 1206

David Ginivan - VP Corporate Communications +44 (0)7471 352 720

Olivia Manser - Director, Investor Relations +44 (0)7947 758 259

 

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Melissa Gardiner / David Daley

 

About Vectura

Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVSEFFDMEFSELI

Related Shares:

VEC.L
FTSE 100 Latest
Value8,275.66
Change0.00